IRTC FINANCIAL STATEMENTS

iRhythm Technologies Inc — balance sheet, income statement and cash flow trends

IRTCiRhythm Technologies Inc

🇺🇸 USA · NASDAQ · Healthcare · Medical Devices

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue787.9 M $+27.4%

Gross Profit559.4 M $+30.3%

Operating Income-21.6 M $—

EBITDA12.6 M $—

Net Income-27.8 M $—

Peer Comparison· Medical Devices

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
IRTC	27.4%	71.0%	1.6%	-3.5%
COH	2.0%	73.0%	24.0%	14.6%
4DX	-26.0%	-396.6%	-818.8%	-3,684.6%
PHIA	-1.9%	45.2%	15.4%	5.5%
SHL	-0.3%	38.0%	19.1%	9.1%
SN	—	68.0%	25.6%	10.1%
Industry median	7.4%	58.9%	5.2%	-5.7%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
IRTC	27.4%	71.0%	1.6%	-3.5%
LIVN	12.4%	67.6%	15.0%	7.5%
HAE	-2.0%	57.3%	21.0%	7.3%
ITGR	6.0%	23.3%	18.0%	7.7%
TMDX	30.2%	59.1%	22.0%	27.0%
AXGN	22.4%	75.0%	-3.5%	-13.2%
Industry median	7.4%	58.9%	5.2%	-5.7%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity161.2 M $16%
Current Liabilities131.8 M $13%
Long-term Liabilities713.4 M $71%

Key Figures

YoY change

Total Assets1 B $+8.7%

Total Liabilities845.2 M $+0.7%

Total Equity161.2 M $+86.0%

Cash & ST Investments549.6 M $+5.6%

Total Debt729.3 M $-0.8%

Net Debt489.1 M $+35.8%

Peer Comparison· Medical Devices

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
IRTC	5.17	452.4%	14.26	16.0%
COH	2.46	22.1%	0.42	69.4%
4DX	6.57	-22.6%	0.71	-20.4%
PHIA	1.32	71.1%	2.03	41.8%
SHL	1.10	84.1%	3.04	40.6%
SN	2.57	62.9%	1.72	50.6%
Industry median	3.28	44.7%	0.82	49.7%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
IRTC	5.17	452.4%	14.26	16.0%
LIVN	1.33	27.6%	-0.95	48.1%
HAE	2.95	153.8%	3.49	33.2%
ITGR	3.75	81.4%	4.13	49.7%
TMDX	6.74	174.8%	2.87	34.4%
AXGN	7.10	8.4%	7.53	84.6%
Industry median	3.28	44.7%	0.82	49.7%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow62.6 M $+31.7%

Capital Expenditures43.8 M $+30.5%

Free Cash Flow18.8 M $+34.5%

Dividends Paid——

Peer Comparison· Medical Devices

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
IRTC	7.9%	2.4%	5.6%	-225.2%
COH	11.2%	8.5%	2.7%	76.6%
4DX	-761.6%	-530.7%	3.7%	20.7%
PHIA	13.0%	10.8%	2.2%	236.4%
SHL	12.2%	8.7%	3.5%	134.0%
SN	20.8%	13.8%	7.0%	205.6%
Industry median	7.2%	1.5%	4.1%	76.6%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
IRTC	7.9%	2.4%	5.6%	-225.2%
LIVN	17.1%	11.2%	5.9%	229.2%
HAE	22.0%	19.5%	2.5%	301.3%
ITGR	10.2%	5.4%	4.9%	133.7%
TMDX	34.6%	23.8%	10.8%	128.1%
AXGN	6.5%	3.8%	2.8%	-49.5%
Industry median	7.2%	1.5%	4.1%	76.6%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on IRTC

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.